Daniel Green Email & Phone Number

San Francisco

Novel spray-dried inhaled formulations of Active Pharmaceutical Ingredients (APIs). Formulations designed to deliver drugs via the deep lung directly to the bloodstream result in rapid, predictable drug absorption while bypassing the GI tract and first-pass metabolism. Inhalation dramatically reduces both bioburden and systemic toxicity.

San Francisco, California, United States

- Report to Vice Chancellor of External Innovation (acting), and supporting spin-out of therapeutic companies from groundbreaking, patented UCSF academic research.- Cofounded Hap10 with Professors Kevan Shokat and Charles Craik to develop immuno-oncology solutions for treating resistance to and enhance efficacy of covalent inhibitors.- Incorporated and negotiated terms for licensing agreements, and equity allocation to UCSF, Founders and Management.- Pitched… Show more - Report to Vice Chancellor of External Innovation (acting), and supporting spin-out of therapeutic companies from groundbreaking, patented UCSF academic research.- Cofounded Hap10 with Professors Kevan Shokat and Charles Craik to develop immuno-oncology solutions for treating resistance to and enhance efficacy of covalent inhibitors.- Incorporated and negotiated terms for licensing agreements, and equity allocation to UCSF, Founders and Management.- Pitched Nephrology/Gastroenterology Development Candidates (anion exchangers) with Professors Onur Cil and Alan Verkman (emeritus) to the Investor community Show less

San Francisco, California, United States

- Started Hap10, Inc., In with Professors Kevan Shokat and Charles Craik to develop immuno-oincology solutions for treating resistance to, and enhancing the efficacy of covalent inhibitors of KRas oncoproteins.- Incorporated and negotiated terms for licensing agreements, and equity allocation to UCSF, Founders and Management.- Led PR effort to highlight groundbreaking research, attract partner interest and drive fundraising.- Secured SAFE note from Seedfolio sponsoring contract… Show more - Started Hap10, Inc., In with Professors Kevan Shokat and Charles Craik to develop immuno-oincology solutions for treating resistance to, and enhancing the efficacy of covalent inhibitors of KRas oncoproteins.- Incorporated and negotiated terms for licensing agreements, and equity allocation to UCSF, Founders and Management.- Led PR effort to highlight groundbreaking research, attract partner interest and drive fundraising.- Secured SAFE note from Seedfolio sponsoring contract research scientists at UCSF and recruitment - Recruited outstanding management team and showcased company to potential corporate partners leading to a collaboration to co-develop Bispecifics with a large BioPharma. Radioligand therapeutic efforts are underway at UCSF.- Developed comprehensive forecasts, project and operating plans. - Hap10 will be poised with the data necessary to complete a Series A raise by 2024. Show less

San Francisco Bay Area

"Pixi" is a Digital Health, Voice-capable platform focused on improving the health and wellness of customers with high value chronic diseases. Tracking patient medication management, keeping Physicians (via Apple Health Record and EMR), Caregivers and Specialty Pharmacies (Drug Supply) in the loop is our focus. Prototype: https://www.youtube.com/watch?v=fPoYAujYioE&t=151s

San Francisco Bay Area

C-Suite consulting and support for business expansion strategies to Biopharmaceutical, Venture and Legal clients. Expertise in Search, Diligence, Valuation, Drug Development, Regulatory Affairs and Commercialization. Disclosable clients include AcelRx, Actelion (J&J), Armetheon, AstraZeneca, Heart Metabolics, La Jolla Pharmaceuticals, UCSF, and Xenon Pharmaceuticals. www.biontrepreneur.com

South San Francisco

Reporting to US President, and in collaboration with Global Business Development (Switzerland), led multifunctional teams to identify and evaluate Specialty and Orphan biopharma companies and assets to expand company footprint beyond the Pulmonary Hypertension core franchise via in-licensing and acquisition. Initiated a comprehensive global analysis of multiple therapeutic areas for later stage assets leading to diligence and bids for both in-licensing and company acquisition.

San Francisco

Co-founded company to develop a glucagon auto-injector to treat severe hypoglycemia in insulin-taking diabetic patients. Successfully negotiated exclusive manufacturing agreements with principal API and component suppliers in Europe/Asia. Raised $4M in Angel financing.

San Francisco

Co-Founded with former ADA President, Prof. Robert Henry, focused on treating diabetes. Built team to develop products through Phase 2a (low dose glucagon) and 2b (levoketoconazole). Co-inventor on issued patents covering hypoglycemia prevention. Raised $33 million in two venture rounds (Series A: Domain, Pequot, Sofinnova. Series B: Joined by Inventages, Mitsui, Pac-Link).

Fremont, Ca

Venture-backed pharmaceutical company focused on “soft drug” medicinal chemistry. Responsible for managing external relationships with client/partner companies.

San Mateo, Ca

Managed operations in 11 western States reporting to President US. Led the regional upsizing, almost tripling the size of the organization from 120 to 325 to simultaneously launch statin Lipitor® (with Pfizer), first in class insulin sensitizer Rezulin® (with Sankyo). US sales exceeded $1B for both products in first year. Launched Celexa® (with Forest). Led unit to 1st place in sales and profits.

Netherlands

Led Marketing, Sales, Medical, Regulatory and Distribution (85 heads). Oversaw rapid integration of Syntex Netherlands. Managed copromote alliances with Amgen (Neupogen®) and Genentech (Pulmozyme®) subsidiaries. Launched Invirase® and Cellcept® into HIV and Transplantationmarkets. Represented Roche at NEFARMA (Dutch), Interpharma (Swiss) Industry Associations.

Basel, Switzerland

Global responsibility for Rocephin®, with product becoming the world’s best-selling injectableantibiotic. Built global marketing team. Sales tripled during tenure to exceed SFr 1 billion in 1992.

Nutley, Nj

Marketing lead for mature products, commercial assessment of biotech in-licensing opportunities. Rotations in Sales, Market Research, Promotion and Market Planning Departments

Pmd, Management

Mba, Finance, Marketing, International Business, Summer Intern At Sandoz (Novartis) In East Hanover, Nj

B.Sc. (Hons); Ms Equivalent, Physiology